Hear Professor Davinder Singh Grewal’s latest in Paediatric Rheumatology. Professor Natasha Nassar shares JAFA’s survey results on JIA’s impact. Professor Catherine Hill discusses transitioning from Children’s to Adult Services. Professor Stephen Colagiuri updates on the Australian Juvenile Arthritis Registry (AJAR).

In JAFA’s 9th Online Symposium on The Future of Paediatric Rheumatology, Dr Ben Whitehead and Dr Pavla Walsh talk about new and emerging medications and standards of care, and what to expect in pain management in the future. They are joined by Australia’s younger generation of paediatric rheumatologists who share their thoughts on the future of treatment and care of JIA and CRDs.

JAFA’s 8th Online Symposium addressed the all-important topic of ensuring optimal and timely medical and home management of acute episodes and intercurrent illness that may arise unexpectedly in children with juvenile arthritis.

JAFA’s latest symposium explores the complex maze of benefits that are potentially available to help meet the increased need for social and health related services in families who have a child with juvenile arthritis with serious physical or other challenges.

This JAFA online symposium shines a light on the link between chronic childhood conditions and mental ill health. Expert speakers outline what is known about the nature and extent of the problem and focus on emerging approaches for reducing the impact of these diseases
on the child and family.

This symposium focusses on the evidence from current and emerging Australian and International research. Top Australian paediatric rheumatology and academic researchers provided updates on
their work including clinical outcomes for Juvenile Arthritis; living guidelines for JIA; health service utilisation and how much exercise is too much or not enough.

In this symposium the pros and cons of current and emerging medications for children with juvenile arthritis. Australian paediatric rheumatologists explore the A to Z of available and emerging medicines for Juvenile Arthritis and the role of the Pharmaceutical Benefits Scheme (PBS).

Australian paediatric rheumatologists discuss services and expectations for young people entering adulthood. The symposium also provides an update on COVID vaccines, treatment and outcomes.

Held on the eve of World Arthritis Day, this symposium features talks by leading Australian paediatric rheumatologists, a senior ophthalmology specialist in Uveitis, and a highly experienced physiotherapist.

Four of Australia’s leading paediatric rheumatologists speak on topical issues in treatment research, and current thinking about the impact of COVID-19 on children with Juvenile Arthritis.